<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29615476</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1479-6805</ISSN><JournalIssue CitedMedium="Internet"><Volume>237</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of endocrinology</Title><ISOAbbreviation>J Endocrinol</ISOAbbreviation></Journal><ArticleTitle>Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>227</EndPage><MedlinePgn>217-227</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1530/JOE-18-0135</ELocationID><ELocationID EIdType="pii" ValidYN="Y">JOE-18-0135</ELocationID><Abstract><AbstractText>Neuronostatin, a somatostatin gene-encoded peptide, exerts important physiological and metabolic actions in diverse tissues. However, the direct biological effects of neuronostatin on pituitary function of humans and primates are still unknown. This study used baboon (<i>Papio anubis</i>) primary pituitary cell cultures, a species that closely models human physiology, to demonstrate that neuronostatin inhibits basal, but not ghrelin-/GnRH-stimulated, growth hormone (GH) and luteinizing hormone (LH) secretion in a dose- and time-dependent fashion, without affecting the secretion of other pituitary hormones (prolactin, ACTH, FSH, thyroid-stimulating hormone (TSH)) or changing mRNA levels. Actions of neuronostatin differs from somatostatin which in this study reduced GH/PRL/ACTH/LH/TSH secretion and GH/PRL/POMC/LH gene expression. Remarkably, we found that inhibitory actions of neuronostatin are likely mediated through: (1) the orphan receptor GPCR107 (found to be highly expressed in pituitary compared to somatostatin-receptors), (2) common (i.e. adenylyl cyclase/protein kinase A/MAPK/extra-/intracellular Ca<sup>2+</sup> mobilization, but not phospholipase C/protein kinase C/mTOR) and distinct (i.e. PI3K) signaling pathways than somatostatin and; (3) dissimilar molecular mechanisms than somatostatin (i.e. upregulation of GPCR107 and downregulation of GHS-R/Kiss1-R expression by neuronostatin and, upregulation of sst1-5 expression by somatostatin). Altogether, the results of this study provide the first evidence that there is a functional neuronostatin signaling circuit, unique from somatostatin, which may work in concert with somatostatin to fine-tune hormone release from somatostropes and gonadotropes.</AbstractText><CopyrightInformation>&#xa9; 2018 Society for Endocrinology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luque</LastName><ForeName>Ra&#xfa;l M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology, Physiology and Immunology, University of C&#xf3;rdoba, Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Universitario Reina Sofia (HURS), Cordoba, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER de la Fisiopatolog&#xed;a de la Obesidad y Nutrici&#xf3;n (CIBERobn), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kineman</LastName><ForeName>Rhonda D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago and Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Endocrinol</MedlineTA><NlmUniqueID>0375363</NlmUniqueID><ISSNLinking>0022-0795</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036361">Peptide Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579289">neuronostatin, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance UI="D013004">Somatostatin</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048530" MajorTopicYN="N">Papio anubis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036361" MajorTopicYN="N">Peptide Hormones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010902" MajorTopicYN="N">Pituitary Gland</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013004" MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GPCR107</Keyword><Keyword MajorTopicYN="N">growth hormone and luteinizing hormone</Keyword><Keyword MajorTopicYN="N">neuronostatin</Keyword><Keyword MajorTopicYN="N">primates</Keyword><Keyword MajorTopicYN="N">signaling pathways</Keyword><Keyword MajorTopicYN="N">somatostatin</Keyword><Keyword MajorTopicYN="N">somatotrope and gonadotrope cells</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29615476</ArticleId><ArticleId IdType="doi">10.1530/JOE-18-0135</ArticleId><ArticleId IdType="pii">JOE-18-0135</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>